TOP TEN perturbations for 1146_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1146_at
Selected probe(set): 203547_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1146_at (203547_at) across 6673 perturbations tested by GENEVESTIGATOR:
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-3.3724422Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):-3.3304825Number of Samples:7 / 12
Experimental | IL-4; GM-CSF study 1 (intermediate) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
VTX-2337 study 1 / 3M-055 study 1
Relative Expression (log2-ratio):-3.2554884Number of Samples:3 / 3
Experimental | VTX-2337 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
Control | 3M-055 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist. |
VTX-2337 study 1 / untreated monocyte sample
Relative Expression (log2-ratio):-3.0776062Number of Samples:3 / 3
Experimental | VTX-2337 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
Control | untreated monocyte sample |
Peripheral blood monocytes isolated from healthy donors. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.969121Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
septic shock study 3 (D1; non-survivor) / normal blood sample
Relative Expression (log2-ratio):-2.9423084Number of Samples:17 / 22
Experimental | septic shock study 3 (D1; non-survivor) |
Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
Control | normal blood sample |
Blood samples from healthy subjects. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-2.9413433Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
monocyte activation study 1 (NOD2L; 24h) / untreated monocyte sample (24h)
Relative Expression (log2-ratio):-2.9360218Number of Samples:5 / 5
Experimental | monocyte activation study 1 (NOD2L; 24h) |
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells. | |
Control | untreated monocyte sample (24h) |
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-2.859558Number of Samples:2 / 2
Experimental | IFN-g; LPS study 1 |
Monocytes LPS/IFN-g activated for 30h. | |
Control | normal resting monocyte sample |
Monocytes resting for 30h. |
septic shock study 3 (D2; non-survivor) / normal blood sample
Relative Expression (log2-ratio):-2.6488924Number of Samples:8 / 22
Experimental | septic shock study 3 (D2; non-survivor) |
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
Control | normal blood sample |
Blood samples from healthy subjects. |